最大型号Epic Supra主动脉瓣生物瓣(29号)的长期结局:推荐尺寸与增大尺寸植入的比较
该研究回顾了2011年至2023年间所有接受Epic Supra生物瓣植入的患者,筛选出360例植入29号瓣膜者,其中部分患者主动脉瓣环≥29 mm(按推荐尺寸),部分<29 mm(增大尺寸)。结果显示30天死亡率为2.8%,再手术率为3.3%,永久起搏器植入率为4.7%,两组间无显著差异;最长随访10年,平均随访50个月,平均跨瓣压差11.3 mmHg,5例(1.4%)因感染性心内膜炎需再次干预。结论认为29号瓣膜可安全用于瓣环<29 mm的患者,可能改善未来瓣中瓣选择。
要点
- 29号Epic Supra生物瓣植入后30天死亡率2.8%,再手术率3.3%,永久起搏器植入率4.7%。
- 增大尺寸植入(瓣环<29 mm)与推荐尺寸植入的短期和长期结果无显著差异。
- 平均跨瓣压差11.3 mmHg,5例(1.4%)因感染性心内膜炎需再次干预。
核心结论
- 29号Epic Supra生物瓣表现出良好的临床和血流动力学性能,可安全植入瓣环小于29 mm的患者。
研究设计与样本
- 回顾性队列研究,纳入2011年至2023年接受Epic Supra生物瓣植入的1845例患者,其中360例植入29号瓣膜,采用倾向性评分匹配比较推荐尺寸与增大尺寸植入组。
主要发现
- 29号瓣膜组平均年龄68(8.9)岁,97.2%为男性,EuroScore II为5.1(1.3; 6.6)。
- 30天死亡率为2.8%,再手术率为3.3%,永久起搏器植入率为4.7%,组间无统计学显著差异。
- 最长随访10年,平均随访50(41)个月,平均跨瓣压差11.3(16.7)mmHg,5例(1.4%)因感染性心内膜炎需再次干预。
临床怎么用
- 对于主动脉瓣环小于29 mm的患者,可考虑植入29号Epic Supra生物瓣以增大有效瓣口面积,为未来瓣中瓣介入预留空间。
局限性
- 本研究为回顾性单中心研究,样本量有限,随访时间最长10年,需更大规模研究验证长期效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate outcomes of aortic valve replacement with the largest available Epic Supra bioprosthesis (size 29). METHODS: We reviewed all patients who received an Epic Supra bioprosthesis between 2011 and 2023 and selected all 29 size prostheses that were implanted either into patients with an aortic annulus of at least 29 mm (sizing as recommended by the manufacturer) or into patients with smaller annuli (upsizing). Short- and long-term results were assessed. Propensity score matching was employed to improve comparability between groups. Kaplan-Meier and log-rank tests were performed to compare survival. RESULTS: Epic Supra bioprostheses were implanted into 1845 patients between 2011 and 2023. Mean age was 69.7 (11.2) years and 79.2% were male. Size 29 was implanted in 360 patients (mean age 68 (8.9) years), and 97.2% were male. EuroScore II was 5.1 (1.3; 6.6). One quarter of cases were performed via parasternal minithoracotomy. Mortality at 30 days was 2.8%, with no significant differences. Need for re-exploration was 3.3% and permanent pacemaker implantation was 4.7% (no statistically significant differences). Longest follow-up was 10 years with a mean of 50 (41) months. Mean prosthetic pressure gradients were 11.3 (16.7) mmHg and aortic valve reoperations/interventions were required in 5 patients (1.4%), all due to infective endocarditis. CONCLUSIONS: This is the largest experience of Epic Supra 29 implantation worldwide. Our results illustrate exemplary clinical and haemodynamic performance. In addition, the 29 size prosthesis can safely be implanted into patients with smaller than 29 mm annulus, which may improve future valve-in-valve options.
引用
- Mukharyamov M, Kirov H, Golovina M, et al. Long-term outcomes of the largest (29) Epic Supra aortic valve bioprosthesis: comparing recommended with upsizing implantation. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40045568. doi:10.1093/icvts/ivaf050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。